I just liked imt from the chart, it's due for a pop any week now. The company just keeps rolling along getting Viruzulin onto the market. I wouldn't count out V. as a contender - even if gene therapy or some other sort of therapy takes over for the majority of treatment, there could still be a market for a soothing symptom-reliever like V. Or maybe I don't understand the technology - well, no matter, truth be told I bought it because the chart said to -g-
Hadn't noticed nvn today until you said that - I let almost half go at .28 and .29 the week before last when the volume dried up on that run, and didn't replace them yet. Probably should have, but I thought it would slide off more.
I really missed the boat on nrt and gns and fmi. I remember making snide remarks about nrt about a year ago, saying that it was pretty hypey. It was about .60 then -g- ..... ah well
Right now I have xlx, imt, hbp, nvn, that's all - xlx has been a bit of a mistake, I'm underwater on it again after today - you were right when you said last summer that it wasn't going anywhere soon. But it will eventually, I think ............ cheers .......... marcos |
